Ask AI
HER2 Positive mBC: New Options
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC

Released: July 25, 2025

Expiration: January 24, 2026

Activity

Progress
1
Course Completed

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:

  • Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancer
  • Interactive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancer
  • Outcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs